https://www.medora.it/2026-03-23T13:21:33.807Zhttps://www.medora.it/rcp-home.html2026-04-01T21:11:54.238Zhttps://www.medora.it/Medical.html2026-04-12T16:50:09.755Zhttps://www.medora.it/Medical/guida-farmacovigilanza.html2026-04-12T16:54:24.933Zhttps://www.medora.it/Medical/guida-farmacovigilanza/eventi-avversi.html2026-04-12T16:58:22.596Zhttps://www.medora.it/Medical/guida-farmacovigilanza/situazioni-speciali.html2026-04-12T16:59:35.552Zhttps://www.medora.it/Medical/guida-farmacovigilanza/situazioni-speciali/errore-terapeutico.html2026-04-12T17:04:40.463Zhttps://www.medora.it/Medical/guida-farmacovigilanza/situazioni-speciali/uso-off-label.html2026-04-12T17:13:18.944Zhttps://www.medora.it/Medical/guida-farmacovigilanza/situazioni-speciali/uso-improprio.html2026-04-12T17:12:33.552Zhttps://www.medora.it/Medical/guida-farmacovigilanza/situazioni-speciali/abuso.html2026-04-12T17:01:56.002Zhttps://www.medora.it/Medical/guida-farmacovigilanza/situazioni-speciali/esposizione-occupazionale.html2026-04-12T17:05:44.266Zhttps://www.medora.it/Medical/guida-farmacovigilanza/situazioni-speciali/sovradosaggio.html2026-04-12T17:11:02.25Zhttps://www.medora.it/Medical/guida-farmacovigilanza/situazioni-speciali/reclami-su-prodotti--problemi-legati-alla-qualita-dei-prodotti.html2026-04-12T17:10:05.356Zhttps://www.medora.it/Medical/guida-farmacovigilanza/situazioni-speciali/interazioni-farmacologiche.html2026-04-12T17:08:03.513Zhttps://www.medora.it/Medical/guida-farmacovigilanza/situazioni-speciali/mancanza-di-efficacia.html2026-04-12T17:09:04.7Zhttps://www.medora.it/Medical/guida-farmacovigilanza/situazioni-speciali/effetti-favorevoli-inattesi.html2026-04-12T17:03:11.714Zhttps://www.medora.it/Medical/guida-farmacovigilanza/situazioni-speciali/gravidanza-e-allattamento.html2026-04-12T17:06:54.706Zhttps://www.medora.it/Medical/richiedi-informazioni.html2026-04-09T11:40:26.988Zhttps://www.medora.it/Medical/oct-retina-forum-2025-roche-symposium.html2026-04-09T11:41:29.965Zhttps://www.medora.it/Medical/video-somministrazione-intravitreale-di-vabysmo.html2026-04-09T11:39:55.834Zhttps://www.medora.it/Medical/highlights-di-letteratura-cancer-immunotherapy/Coagulation-factor-VIII-biological-basis-of-emerging-hemophilia-A-therapies.html2026-04-23T14:44:33.088Zhttps://www.medora.it/Medical/highlights-di-letteratura-cancer-immunotherapy/Combination-targeted-therapy-in-relapsed-diffuse-large-B-cell-lymphoma.html2026-04-23T14:44:33.121Zhttps://www.medora.it/Medical/highlights-di-letteratura-cancer-immunotherapy/Epcoritamab-monotherapy-in-patients-with-relapsed-or-refractory-follicular-lymphoma-EPCORE-NHL-1-a-phase-2-cohort-of-a-single-arm-multicentre-study1.html2026-04-23T14:44:33.19Zhttps://www.medora.it/Medical/highlights-di-letteratura-cancer-immunotherapy/Frontline-treatment-of-follicular-lymphoma-what-will-it-take-to-change-current-practice.html2026-04-23T14:44:33.228Zhttps://www.medora.it/Medical/highlights-di-letteratura-cancer-immunotherapy/Glofitamab-in-relapsed-refractory-mantle-cell-lymphoma-results-from-a-phase-I-II-study.html2026-04-23T14:44:33.27Zhttps://www.medora.it/Medical/highlights-di-letteratura-cancer-immunotherapy/Glofitamab-plus-gemcitabine-and-oxaliplatin-GemOx-versus-rituximab-GemOx-for-relapsed-or-refractory-diffuse-large-B-cell-lymphoma-STARGLO-a-global-phase-3-randomised-open-label-trial.html2026-04-23T14:44:33.317Zhttps://www.medora.it/Medical/highlights-di-letteratura-cancer-immunotherapy/Identification-risk-factors-and-clinical-course-of-CNS-relapse-in-DLBCL-patients-across-19-prospective-phase-2-and-3-trials-a-LYSA-and-GLA-DSHNHL-collaboration1.html2026-04-23T14:44:33.358Zhttps://www.medora.it/Medical/highlights-di-letteratura-cancer-immunotherapy/International-Society-on-Thrombointernational-society-on-thrombosis-and-haemostasis-clinical-practice-guideline-for-treatment-of-congenital-haemophilia-a-critical-appraisal.html2026-04-23T14:44:33.398Zhttps://www.medora.it/Medical/highlights-di-letteratura-cancer-immunotherapy/International-Society-on-Thrombosis-and-Haemostasis-clinical-practice-guideline-for-treatment-of-congenital-hemophilia-A-and-B-based-on-the-Grading-of-Recommendations-Assessment-Development-and-Evaluation-methodology.html2026-04-23T14:44:33.434Zhttps://www.medora.it/Medical/highlights-di-letteratura-cancer-immunotherapy/Late-adverse-events-after-chimeric-antigen-receptor-T-cell-therapy-for-patients-with-aggressive-B-cell-Non-Hodgkin-lymphoma.html2026-04-23T14:44:33.475Zhttps://www.medora.it/Medical/highlights-di-letteratura-cancer-immunotherapy/Loncastuximab-tesirine-in-relapsed-refractory-diffuse-large-B-cell-lymphoma-long-term-efficacy-and-safety-from-the-phase-II-LOTIS-2-study.html2026-04-23T14:44:33.507Zhttps://www.medora.it/Medical/highlights-di-letteratura-cancer-immunotherapy/Long-term-3-year-follow-up-of-mosunetuzumab-in-relapsed-or-refractory-follicular-lymphoma-after-2-or-more-prior-therapies.html2026-04-23T14:44:33.549Zhttps://www.medora.it/Medical/highlights-di-letteratura-cancer-immunotherapy/Pain-related-quality-of-life-outcomes-in-people-with-haemophilia-A-receiving-emicizumab-a-post-hoc-analysis-of-the-HAVEN-1-3-and-4-and-STASEY-studies.html2026-04-23T14:44:33.647Zhttps://www.medora.it/Medical/highlights-di-letteratura-cancer-immunotherapy/Polatuzumab-vedotin-plus-bendamustine-and-rituximab-or-obinutuzumab-in-relapsed-refractory-follicular-lymphoma-a-phase-Ib-II-study.html2026-04-23T14:44:33.682Zhttps://www.medora.it/Medical/highlights-di-letteratura-cancer-immunotherapy/Tumor-infiltrating-lymphocytes-and-survival-outcomes-in-early-ERBB2-positive-breast-cancer-10-year-analysis-of-the-ShortHER-randomized-clinical-trial.html2026-04-23T14:44:33.718Zhttps://www.medora.it/Medical/highlights-di-letteratura-cancer-immunotherapy/advancing-hemophilia-treatment-gene-therapy.html2026-04-23T14:44:33.755Zhttps://www.medora.it/Medical/highlights-di-letteratura-cancer-immunotherapy/an-immunogenetic-basis-for-lung-cancer-risk.html2026-04-23T14:44:33.793Zhttps://www.medora.it/Medical/highlights-di-letteratura-cancer-immunotherapy/artificial-intelligence-hemophilia-management-future-directions.html2026-04-23T14:44:33.83Zhttps://www.medora.it/Medical/highlights-di-letteratura-cancer-immunotherapy/cd19-car-t-primary-mediastinal-lbcl-cibmtr-analysis.html2026-04-23T14:44:33.867Zhttps://www.medora.it/Medical/highlights-di-letteratura-cancer-immunotherapy/clinical-outcomes-of-total-knee-arthroplasty-in-patients-who-have-hemophilic-arthropathy-a-prospective-study.html2026-04-23T14:44:33.908Zhttps://www.medora.it/Medical/highlights-di-letteratura-cancer-immunotherapy/clotting-factor-concentrates-hemophilia-children.html2026-04-23T14:44:33.946Zhttps://www.medora.it/Medical/highlights-di-letteratura-cancer-immunotherapy/concizumab-prophylaxis-in-people-with-haemophilia-a-or-haemophilia-b-without-inhibitors-explorer8-a-prospective-multicentre-open-label-randomised-phase-3a-trial.html2026-04-23T14:44:33.996Zhttps://www.medora.it/Medical/highlights-di-letteratura-cancer-immunotherapy/cost-effectiveness-emicizumab-review.html2026-04-23T14:44:34.067Zhttps://www.medora.it/Medical/highlights-di-letteratura-cancer-immunotherapy/durvalumab-with-or-without-tremelimumab-in-combination-with-chemotherapy-as-first-line-therapy-for-metastatic-non-small-cell-lung-cancer-the-phase-iii-poseidon-study.html2026-04-23T14:44:34.106Zhttps://www.medora.it/Medical/highlights-di-letteratura-cancer-immunotherapy/efficacy-safety-satisfaction-emicizumab-hemophilia-a-systematic-review.html2026-04-23T14:44:34.147Zhttps://www.medora.it/Medical/highlights-di-letteratura-cancer-immunotherapy/emicizumab-and-unmet-needs-of-patients-with-hemophilia-a-who-are-managed-with-replacement-therapies.html2026-04-23T14:44:34.197Zhttps://www.medora.it/Medical/highlights-di-letteratura-cancer-immunotherapy/emicizumab-untreated-hemophilia-a-study.html2026-04-23T14:44:34.234Zhttps://www.medora.it/Medical/highlights-di-letteratura-cancer-immunotherapy/extending-health-equity-to-people-with-moderate-and-mild-hemophilia-a-revisiting-the-haven-6-trial.html2026-04-23T14:44:34.269Zhttps://www.medora.it/Medical/highlights-di-letteratura-cancer-immunotherapy/first-in-human-study-nxt007-factor-viii-mimetic-antibody.html2026-04-23T14:44:34.302Zhttps://www.medora.it/Medical/highlights-di-letteratura-cancer-immunotherapy/gene-therapy-hemophilia-care-pathway-isth.html2026-04-23T14:44:34.344Zhttps://www.medora.it/Medical/highlights-di-letteratura-cancer-immunotherapy/gene-therapy-hemophilia-lab-challenges.html2026-04-23T14:44:34.381Zhttps://www.medora.it/Medical/highlights-di-letteratura-cancer-immunotherapy/glofitamab-polatuzumab-efficacy-safety-rr-lbcl-hgbcl-phase1b-2.html2026-04-23T14:44:34.421Zhttps://www.medora.it/Medical/highlights-di-letteratura-cancer-immunotherapy/glofitamab-vs-epcoritamab-cost-analysis-rr-dlbcl.html2026-04-23T14:44:34.465Zhttps://www.medora.it/Medical/highlights-di-letteratura-cancer-immunotherapy/hemophilia-joint-health-score-model-economic-evaluation-prophylaxis.html2026-04-23T14:44:34.504Zhttps://www.medora.it/Medical/highlights-di-letteratura-cancer-immunotherapy/hrqol-physical-activity-joint-health-emicizumab.html2026-04-23T14:44:34.536Zhttps://www.medora.it/Medical/highlights-di-letteratura-cancer-immunotherapy/large-b-cell-lymphoma-eha-clinical-practice-guidelines-diagnosis-treatment-follow-up.html2026-04-23T14:44:34.597Zhttps://www.medora.it/Medical/highlights-di-letteratura-cancer-immunotherapy/lisocabtagene-maraleucel-vs-standard-care-second-line-rr-lbcl-transform-phase3-3yr-followup.html2026-04-23T14:44:34.649Zhttps://www.medora.it/Medical/highlights-di-letteratura-cancer-immunotherapy/marstacimab-treatment-hemophilia-a-b.html2026-04-23T14:44:34.705Zhttps://www.medora.it/Medical/highlights-di-letteratura-cancer-immunotherapy/mosunetuzumab-polatuzumab-transplant-ineligible-rr-lbcl-sunmo-phase3.html2026-04-23T14:44:34.744Zhttps://www.medora.it/Medical/highlights-di-letteratura-cancer-immunotherapy/nupower-nuwiq-perioperative-hemophilia-a.html2026-04-23T14:44:34.783Zhttps://www.medora.it/Medical/highlights-di-letteratura-cancer-immunotherapy/nxt007-first-in-human-study.html2026-04-23T14:44:34.818Zhttps://www.medora.it/Medical/highlights-di-letteratura-cancer-immunotherapy/orthopaedic-surgery-hemophilia-ehl-fusion.html2026-04-23T14:44:34.857Zhttps://www.medora.it/Medical/highlights-di-letteratura-cancer-immunotherapy/patient-perspective-on-disease-burden-and-gene-therapy-for-hemophilia-a-and-b-the-haemvolution-for-patients-italian-survey.html2026-04-23T14:44:34.897Zhttps://www.medora.it/Medical/highlights-di-letteratura-cancer-immunotherapy/pharmacokinetics-concizumab-hemophilia.html2026-04-23T14:44:34.932Zhttps://www.medora.it/Medical/highlights-di-letteratura-cancer-immunotherapy/polarix-subgroup-analysis-older-patients-60-dlbcl-phase3.html2026-04-23T14:44:34.966Zhttps://www.medora.it/Medical/highlights-di-letteratura-cancer-immunotherapy/review-management-relapsed-refractory-follicular-lymphoma-italian-perspective.html2026-04-23T14:44:35Zhttps://www.medora.it/Medical/highlights-di-letteratura-cancer-immunotherapy/rituximab-bendamustine-cytarabine-venetoclax-older-highrisk-mcl-fil-v-rbac-phase2.html2026-04-23T14:44:35.042Zhttps://www.medora.it/Medical/highlights-di-letteratura-cancer-immunotherapy/safety-and-efficacy-of-valoctocogene-roxaparvovec-with-prophylactic-glucocorticoids-1-year-results-from-the-phase-3b-single-arm-open-label-gener8-3-study.html2026-04-23T14:44:35.077Zhttps://www.medora.it/Medical/highlights-di-letteratura-cancer-immunotherapy/tafasitamab-lenalidomide-salvage-therapy-dlbcl-geltamo-real-world.html2026-04-23T14:44:35.114Zhttps://www.medora.it/Medical/highlights-di-letteratura-cancer-immunotherapy/therapeutic-innovations-hemophilia-reinvestment.html2026-04-23T14:44:35.158Zhttps://www.medora.it/Medical/highlights-di-letteratura-cancer-immunotherapy/transcar-real-world-cd19-car-t-rr-transformed-indolent-lymphomas.html2026-04-23T14:44:35.195Zhttps://www.medora.it/Medical/highlights-di-letteratura-cancer-immunotherapy/transforming-hemophilia-care-therapeutic-innovations-challenges.html2026-04-23T14:44:35.237Zhttps://www.medora.it/Medical/highlights-di-letteratura-cancer-immunotherapy/treatment-of-bleeding-episodes-with-efanesoctocog-alfa-in-previously-treated-patients-with-severe-hemophilia-a-in-the-phase-3-xtend-1-study.html2026-04-23T14:44:35.278Zhttps://www.medora.it/Medical/highlights-di-letteratura-cancer-immunotherapy/tsubasa-study-quality-daily-life-hemophilia-a-emicizumab.html2026-04-23T14:44:35.317Zhttps://www.medora.it/Medical/highlights-di-letteratura-hematology/Coagulation-factor-VIII-biological-basis-of-emerging-hemophilia-A-therapies.html2026-04-23T14:44:35.364Zhttps://www.medora.it/Medical/highlights-di-letteratura-hematology/Combination-targeted-therapy-in-relapsed-diffuse-large-B-cell-lymphoma.html2026-04-23T14:44:35.421Zhttps://www.medora.it/Medical/highlights-di-letteratura-hematology/Epcoritamab-monotherapy-in-patients-with-relapsed-or-refractory-follicular-lymphoma-EPCORE-NHL-1-a-phase-2-cohort-of-a-single-arm-multicentre-study1.html2026-04-23T14:44:35.519Zhttps://www.medora.it/Medical/highlights-di-letteratura-hematology/Frontline-treatment-of-follicular-lymphoma-what-will-it-take-to-change-current-practice.html2026-04-23T14:44:35.569Zhttps://www.medora.it/Medical/highlights-di-letteratura-hematology/Glofitamab-in-relapsed-refractory-mantle-cell-lymphoma-results-from-a-phase-I-II-study.html2026-04-23T14:44:35.605Zhttps://www.medora.it/Medical/highlights-di-letteratura-hematology/Glofitamab-plus-gemcitabine-and-oxaliplatin-GemOx-versus-rituximab-GemOx-for-relapsed-or-refractory-diffuse-large-B-cell-lymphoma-STARGLO-a-global-phase-3-randomised-open-label-trial.html2026-04-23T14:44:35.643Zhttps://www.medora.it/Medical/highlights-di-letteratura-hematology/Identification-risk-factors-and-clinical-course-of-CNS-relapse-in-DLBCL-patients-across-19-prospective-phase-2-and-3-trials-a-LYSA-and-GLA-DSHNHL-collaboration1.html2026-04-23T14:44:35.681Zhttps://www.medora.it/Medical/highlights-di-letteratura-hematology/International-Society-on-Thrombointernational-society-on-thrombosis-and-haemostasis-clinical-practice-guideline-for-treatment-of-congenital-haemophilia-a-critical-appraisal.html2026-04-23T14:44:35.726Zhttps://www.medora.it/Medical/highlights-di-letteratura-hematology/International-Society-on-Thrombosis-and-Haemostasis-clinical-practice-guideline-for-treatment-of-congenital-hemophilia-A-and-B-based-on-the-Grading-of-Recommendations-Assessment-Development-and-Evaluation-methodology.html2026-04-23T14:44:35.802Zhttps://www.medora.it/Medical/highlights-di-letteratura-hematology/Late-adverse-events-after-chimeric-antigen-receptor-T-cell-therapy-for-patients-with-aggressive-B-cell-Non-Hodgkin-lymphoma.html2026-04-23T14:44:35.851Zhttps://www.medora.it/Medical/highlights-di-letteratura-hematology/Loncastuximab-tesirine-in-relapsed-refractory-diffuse-large-B-cell-lymphoma-long-term-efficacy-and-safety-from-the-phase-II-LOTIS-2-study.html2026-04-23T14:44:35.924Zhttps://www.medora.it/Medical/highlights-di-letteratura-hematology/Long-term-3-year-follow-up-of-mosunetuzumab-in-relapsed-or-refractory-follicular-lymphoma-after-2-or-more-prior-therapies.html2026-04-23T14:44:35.966Zhttps://www.medora.it/Medical/highlights-di-letteratura-hematology/Pain-related-quality-of-life-outcomes-in-people-with-haemophilia-A-receiving-emicizumab-a-post-hoc-analysis-of-the-HAVEN-1-3-and-4-and-STASEY-studies.html2026-04-23T14:44:36.007Zhttps://www.medora.it/Medical/highlights-di-letteratura-hematology/Polatuzumab-vedotin-plus-bendamustine-and-rituximab-or-obinutuzumab-in-relapsed-refractory-follicular-lymphoma-a-phase-Ib-II-study.html2026-04-23T14:44:36.096Zhttps://www.medora.it/Medical/highlights-di-letteratura-hematology/Tumor-infiltrating-lymphocytes-and-survival-outcomes-in-early-ERBB2-positive-breast-cancer-10-year-analysis-of-the-ShortHER-randomized-clinical-trial.html2026-04-23T14:44:36.143Zhttps://www.medora.it/Medical/highlights-di-letteratura-hematology/advancing-hemophilia-treatment-gene-therapy.html2026-04-23T14:44:36.185Zhttps://www.medora.it/Medical/highlights-di-letteratura-hematology/an-immunogenetic-basis-for-lung-cancer-risk.html2026-04-23T14:44:36.218Zhttps://www.medora.it/Medical/highlights-di-letteratura-hematology/artificial-intelligence-hemophilia-management-future-directions.html2026-04-23T14:44:36.258Zhttps://www.medora.it/Medical/highlights-di-letteratura-hematology/cd19-car-t-primary-mediastinal-lbcl-cibmtr-analysis.html2026-04-23T14:44:36.298Zhttps://www.medora.it/Medical/highlights-di-letteratura-hematology/clinical-outcomes-of-total-knee-arthroplasty-in-patients-who-have-hemophilic-arthropathy-a-prospective-study.html2026-04-23T14:44:36.338Zhttps://www.medora.it/Medical/highlights-di-letteratura-hematology/clotting-factor-concentrates-hemophilia-children.html2026-04-23T14:44:36.38Zhttps://www.medora.it/Medical/highlights-di-letteratura-hematology/concizumab-prophylaxis-in-people-with-haemophilia-a-or-haemophilia-b-without-inhibitors-explorer8-a-prospective-multicentre-open-label-randomised-phase-3a-trial.html2026-04-23T14:44:36.43Zhttps://www.medora.it/Medical/highlights-di-letteratura-hematology/cost-effectiveness-emicizumab-review.html2026-04-23T14:44:36.466Zhttps://www.medora.it/Medical/highlights-di-letteratura-hematology/durvalumab-with-or-without-tremelimumab-in-combination-with-chemotherapy-as-first-line-therapy-for-metastatic-non-small-cell-lung-cancer-the-phase-iii-poseidon-study.html2026-04-23T14:44:36.526Zhttps://www.medora.it/Medical/highlights-di-letteratura-hematology/efficacy-safety-satisfaction-emicizumab-hemophilia-a-systematic-review.html2026-04-23T14:44:36.585Zhttps://www.medora.it/Medical/highlights-di-letteratura-hematology/emicizumab-and-unmet-needs-of-patients-with-hemophilia-a-who-are-managed-with-replacement-therapies.html2026-04-23T14:44:36.629Zhttps://www.medora.it/Medical/highlights-di-letteratura-hematology/emicizumab-untreated-hemophilia-a-study.html2026-04-23T14:44:36.675Zhttps://www.medora.it/Medical/highlights-di-letteratura-hematology/extending-health-equity-to-people-with-moderate-and-mild-hemophilia-a-revisiting-the-haven-6-trial.html2026-04-23T14:44:36.713Zhttps://www.medora.it/Medical/highlights-di-letteratura-hematology/first-in-human-study-nxt007-factor-viii-mimetic-antibody.html2026-04-23T14:44:36.766Zhttps://www.medora.it/Medical/highlights-di-letteratura-hematology/gene-therapy-hemophilia-care-pathway-isth.html2026-04-23T14:44:36.823Zhttps://www.medora.it/Medical/highlights-di-letteratura-hematology/gene-therapy-hemophilia-lab-challenges.html2026-04-23T14:44:36.867Zhttps://www.medora.it/Medical/highlights-di-letteratura-hematology/glofitamab-polatuzumab-efficacy-safety-rr-lbcl-hgbcl-phase1b-2.html2026-04-23T14:44:36.936Zhttps://www.medora.it/Medical/highlights-di-letteratura-hematology/glofitamab-vs-epcoritamab-cost-analysis-rr-dlbcl.html2026-04-23T14:44:36.978Zhttps://www.medora.it/Medical/highlights-di-letteratura-hematology/hemophilia-joint-health-score-model-economic-evaluation-prophylaxis.html2026-04-23T14:44:37.11Zhttps://www.medora.it/Medical/highlights-di-letteratura-hematology/hrqol-physical-activity-joint-health-emicizumab.html2026-04-23T14:44:37.162Zhttps://www.medora.it/Medical/highlights-di-letteratura-hematology/large-b-cell-lymphoma-eha-clinical-practice-guidelines-diagnosis-treatment-follow-up.html2026-04-23T14:44:37.201Zhttps://www.medora.it/Medical/highlights-di-letteratura-hematology/lisocabtagene-maraleucel-vs-standard-care-second-line-rr-lbcl-transform-phase3-3yr-followup.html2026-04-23T14:44:37.246Zhttps://www.medora.it/Medical/highlights-di-letteratura-hematology/marstacimab-treatment-hemophilia-a-b.html2026-04-23T14:44:37.287Zhttps://www.medora.it/Medical/highlights-di-letteratura-hematology/mosunetuzumab-polatuzumab-transplant-ineligible-rr-lbcl-sunmo-phase3.html2026-04-23T14:44:37.329Zhttps://www.medora.it/Medical/highlights-di-letteratura-hematology/nupower-nuwiq-perioperative-hemophilia-a.html2026-04-23T14:44:37.373Zhttps://www.medora.it/Medical/highlights-di-letteratura-hematology/nxt007-first-in-human-study.html2026-04-23T14:44:37.42Zhttps://www.medora.it/Medical/highlights-di-letteratura-hematology/orthopaedic-surgery-hemophilia-ehl-fusion.html2026-04-23T14:44:37.453Zhttps://www.medora.it/Medical/highlights-di-letteratura-hematology/patient-perspective-on-disease-burden-and-gene-therapy-for-hemophilia-a-and-b-the-haemvolution-for-patients-italian-survey.html2026-04-23T14:44:37.498Zhttps://www.medora.it/Medical/highlights-di-letteratura-hematology/pharmacokinetics-concizumab-hemophilia.html2026-04-23T14:44:37.548Zhttps://www.medora.it/Medical/highlights-di-letteratura-hematology/polarix-subgroup-analysis-older-patients-60-dlbcl-phase3.html2026-04-23T14:44:37.585Zhttps://www.medora.it/Medical/highlights-di-letteratura-hematology/review-management-relapsed-refractory-follicular-lymphoma-italian-perspective.html2026-04-23T14:44:37.621Zhttps://www.medora.it/Medical/highlights-di-letteratura-hematology/rituximab-bendamustine-cytarabine-venetoclax-older-highrisk-mcl-fil-v-rbac-phase2.html2026-04-23T14:44:37.664Zhttps://www.medora.it/Medical/highlights-di-letteratura-hematology/safety-and-efficacy-of-valoctocogene-roxaparvovec-with-prophylactic-glucocorticoids-1-year-results-from-the-phase-3b-single-arm-open-label-gener8-3-study.html2026-04-23T14:44:37.703Zhttps://www.medora.it/Medical/highlights-di-letteratura-hematology/tafasitamab-lenalidomide-salvage-therapy-dlbcl-geltamo-real-world.html2026-04-23T14:44:37.758Zhttps://www.medora.it/Medical/highlights-di-letteratura-hematology/therapeutic-innovations-hemophilia-reinvestment.html2026-04-23T14:44:37.857Zhttps://www.medora.it/Medical/highlights-di-letteratura-hematology/transcar-real-world-cd19-car-t-rr-transformed-indolent-lymphomas.html2026-04-23T14:44:37.9Zhttps://www.medora.it/Medical/highlights-di-letteratura-hematology/transforming-hemophilia-care-therapeutic-innovations-challenges.html2026-04-23T14:44:37.933Zhttps://www.medora.it/Medical/highlights-di-letteratura-hematology/treatment-of-bleeding-episodes-with-efanesoctocog-alfa-in-previously-treated-patients-with-severe-hemophilia-a-in-the-phase-3-xtend-1-study.html2026-04-23T14:44:37.975Zhttps://www.medora.it/Medical/highlights-di-letteratura-hematology/tsubasa-study-quality-daily-life-hemophilia-a-emicizumab.html2026-04-23T14:44:38.04Zhttps://www.medora.it/Medical/highlights-di-letteratura-hemophilia/Coagulation-factor-VIII-biological-basis-of-emerging-hemophilia-A-therapies.html2026-04-23T14:44:38.093Zhttps://www.medora.it/Medical/highlights-di-letteratura-hemophilia/Combination-targeted-therapy-in-relapsed-diffuse-large-B-cell-lymphoma.html2026-04-23T14:44:38.182Zhttps://www.medora.it/Medical/highlights-di-letteratura-hemophilia/Epcoritamab-monotherapy-in-patients-with-relapsed-or-refractory-follicular-lymphoma-EPCORE-NHL-1-a-phase-2-cohort-of-a-single-arm-multicentre-study1.html2026-04-23T14:44:38.28Zhttps://www.medora.it/Medical/highlights-di-letteratura-hemophilia/Frontline-treatment-of-follicular-lymphoma-what-will-it-take-to-change-current-practice.html2026-04-23T14:44:38.343Zhttps://www.medora.it/Medical/highlights-di-letteratura-hemophilia/Glofitamab-in-relapsed-refractory-mantle-cell-lymphoma-results-from-a-phase-I-II-study.html2026-04-23T14:44:38.413Zhttps://www.medora.it/Medical/highlights-di-letteratura-hemophilia/Glofitamab-plus-gemcitabine-and-oxaliplatin-GemOx-versus-rituximab-GemOx-for-relapsed-or-refractory-diffuse-large-B-cell-lymphoma-STARGLO-a-global-phase-3-randomised-open-label-trial.html2026-04-23T14:44:38.472Zhttps://www.medora.it/Medical/highlights-di-letteratura-hemophilia/Identification-risk-factors-and-clinical-course-of-CNS-relapse-in-DLBCL-patients-across-19-prospective-phase-2-and-3-trials-a-LYSA-and-GLA-DSHNHL-collaboration1.html2026-04-23T14:44:38.531Zhttps://www.medora.it/Medical/highlights-di-letteratura-hemophilia/International-Society-on-Thrombointernational-society-on-thrombosis-and-haemostasis-clinical-practice-guideline-for-treatment-of-congenital-haemophilia-a-critical-appraisal.html2026-04-23T14:44:38.579Zhttps://www.medora.it/Medical/highlights-di-letteratura-hemophilia/International-Society-on-Thrombosis-and-Haemostasis-clinical-practice-guideline-for-treatment-of-congenital-hemophilia-A-and-B-based-on-the-Grading-of-Recommendations-Assessment-Development-and-Evaluation-methodology.html2026-04-23T14:44:38.617Zhttps://www.medora.it/Medical/highlights-di-letteratura-hemophilia/Late-adverse-events-after-chimeric-antigen-receptor-T-cell-therapy-for-patients-with-aggressive-B-cell-Non-Hodgkin-lymphoma.html2026-04-23T14:44:38.674Zhttps://www.medora.it/Medical/highlights-di-letteratura-hemophilia/Loncastuximab-tesirine-in-relapsed-refractory-diffuse-large-B-cell-lymphoma-long-term-efficacy-and-safety-from-the-phase-II-LOTIS-2-study.html2026-04-23T14:44:38.711Zhttps://www.medora.it/Medical/highlights-di-letteratura-hemophilia/Long-term-3-year-follow-up-of-mosunetuzumab-in-relapsed-or-refractory-follicular-lymphoma-after-2-or-more-prior-therapies.html2026-04-23T14:44:38.75Zhttps://www.medora.it/Medical/highlights-di-letteratura-hemophilia/Pain-related-quality-of-life-outcomes-in-people-with-haemophilia-A-receiving-emicizumab-a-post-hoc-analysis-of-the-HAVEN-1-3-and-4-and-STASEY-studies.html2026-04-23T14:44:38.801Zhttps://www.medora.it/Medical/highlights-di-letteratura-hemophilia/Polatuzumab-vedotin-plus-bendamustine-and-rituximab-or-obinutuzumab-in-relapsed-refractory-follicular-lymphoma-a-phase-Ib-II-study.html2026-04-23T14:44:38.848Zhttps://www.medora.it/Medical/highlights-di-letteratura-hemophilia/Tumor-infiltrating-lymphocytes-and-survival-outcomes-in-early-ERBB2-positive-breast-cancer-10-year-analysis-of-the-ShortHER-randomized-clinical-trial.html2026-04-23T14:44:38.881Zhttps://www.medora.it/Medical/highlights-di-letteratura-hemophilia/advancing-hemophilia-treatment-gene-therapy.html2026-04-23T14:44:38.919Zhttps://www.medora.it/Medical/highlights-di-letteratura-hemophilia/an-immunogenetic-basis-for-lung-cancer-risk.html2026-04-23T14:44:38.954Zhttps://www.medora.it/Medical/highlights-di-letteratura-hemophilia/artificial-intelligence-hemophilia-management-future-directions.html2026-04-23T14:44:38.997Zhttps://www.medora.it/Medical/highlights-di-letteratura-hemophilia/cd19-car-t-primary-mediastinal-lbcl-cibmtr-analysis.html2026-04-23T14:44:39.036Zhttps://www.medora.it/Medical/highlights-di-letteratura-hemophilia/clinical-outcomes-of-total-knee-arthroplasty-in-patients-who-have-hemophilic-arthropathy-a-prospective-study.html2026-04-23T14:44:39.071Zhttps://www.medora.it/Medical/highlights-di-letteratura-hemophilia/clotting-factor-concentrates-hemophilia-children.html2026-04-23T14:44:39.118Zhttps://www.medora.it/Medical/highlights-di-letteratura-hemophilia/concizumab-prophylaxis-in-people-with-haemophilia-a-or-haemophilia-b-without-inhibitors-explorer8-a-prospective-multicentre-open-label-randomised-phase-3a-trial.html2026-04-23T14:44:39.156Zhttps://www.medora.it/Medical/highlights-di-letteratura-hemophilia/cost-effectiveness-emicizumab-review.html2026-04-23T14:44:39.189Zhttps://www.medora.it/Medical/highlights-di-letteratura-hemophilia/durvalumab-with-or-without-tremelimumab-in-combination-with-chemotherapy-as-first-line-therapy-for-metastatic-non-small-cell-lung-cancer-the-phase-iii-poseidon-study.html2026-04-23T14:44:39.224Zhttps://www.medora.it/Medical/highlights-di-letteratura-hemophilia/efficacy-safety-satisfaction-emicizumab-hemophilia-a-systematic-review.html2026-04-23T14:44:39.311Zhttps://www.medora.it/Medical/highlights-di-letteratura-hemophilia/emicizumab-and-unmet-needs-of-patients-with-hemophilia-a-who-are-managed-with-replacement-therapies.html2026-04-23T14:44:39.355Zhttps://www.medora.it/Medical/highlights-di-letteratura-hemophilia/emicizumab-untreated-hemophilia-a-study.html2026-04-23T14:44:39.398Zhttps://www.medora.it/Medical/highlights-di-letteratura-hemophilia/extending-health-equity-to-people-with-moderate-and-mild-hemophilia-a-revisiting-the-haven-6-trial.html2026-04-23T14:44:39.45Zhttps://www.medora.it/Medical/highlights-di-letteratura-hemophilia/first-in-human-study-nxt007-factor-viii-mimetic-antibody.html2026-04-23T14:44:39.485Zhttps://www.medora.it/Medical/highlights-di-letteratura-hemophilia/gene-therapy-hemophilia-care-pathway-isth.html2026-04-23T14:44:39.543Zhttps://www.medora.it/Medical/highlights-di-letteratura-hemophilia/gene-therapy-hemophilia-lab-challenges.html2026-04-23T14:44:39.582Zhttps://www.medora.it/Medical/highlights-di-letteratura-hemophilia/glofitamab-polatuzumab-efficacy-safety-rr-lbcl-hgbcl-phase1b-2.html2026-04-23T14:44:39.62Zhttps://www.medora.it/Medical/highlights-di-letteratura-hemophilia/glofitamab-vs-epcoritamab-cost-analysis-rr-dlbcl.html2026-04-23T14:44:39.657Zhttps://www.medora.it/Medical/highlights-di-letteratura-hemophilia/hemophilia-joint-health-score-model-economic-evaluation-prophylaxis.html2026-04-23T14:44:39.696Zhttps://www.medora.it/Medical/highlights-di-letteratura-hemophilia/hrqol-physical-activity-joint-health-emicizumab.html2026-04-23T14:44:39.735Zhttps://www.medora.it/Medical/highlights-di-letteratura-hemophilia/large-b-cell-lymphoma-eha-clinical-practice-guidelines-diagnosis-treatment-follow-up.html2026-04-23T14:44:39.78Zhttps://www.medora.it/Medical/highlights-di-letteratura-hemophilia/lisocabtagene-maraleucel-vs-standard-care-second-line-rr-lbcl-transform-phase3-3yr-followup.html2026-04-23T14:44:39.82Zhttps://www.medora.it/Medical/highlights-di-letteratura-hemophilia/marstacimab-treatment-hemophilia-a-b.html2026-04-23T14:44:39.859Zhttps://www.medora.it/Medical/highlights-di-letteratura-hemophilia/mosunetuzumab-polatuzumab-transplant-ineligible-rr-lbcl-sunmo-phase3.html2026-04-23T14:44:39.898Zhttps://www.medora.it/Medical/highlights-di-letteratura-hemophilia/nupower-nuwiq-perioperative-hemophilia-a.html2026-04-23T14:44:39.944Zhttps://www.medora.it/Medical/highlights-di-letteratura-hemophilia/nxt007-first-in-human-study.html2026-04-23T14:44:39.994Zhttps://www.medora.it/Medical/highlights-di-letteratura-hemophilia/orthopaedic-surgery-hemophilia-ehl-fusion.html2026-04-23T14:44:40.053Zhttps://www.medora.it/Medical/highlights-di-letteratura-hemophilia/patient-perspective-on-disease-burden-and-gene-therapy-for-hemophilia-a-and-b-the-haemvolution-for-patients-italian-survey.html2026-04-23T14:44:40.095Zhttps://www.medora.it/Medical/highlights-di-letteratura-hemophilia/pharmacokinetics-concizumab-hemophilia.html2026-04-23T14:44:40.138Zhttps://www.medora.it/Medical/highlights-di-letteratura-hemophilia/polarix-subgroup-analysis-older-patients-60-dlbcl-phase3.html2026-04-23T14:44:40.192Zhttps://www.medora.it/Medical/highlights-di-letteratura-hemophilia/review-management-relapsed-refractory-follicular-lymphoma-italian-perspective.html2026-04-23T14:44:40.241Zhttps://www.medora.it/Medical/highlights-di-letteratura-hemophilia/rituximab-bendamustine-cytarabine-venetoclax-older-highrisk-mcl-fil-v-rbac-phase2.html2026-04-23T14:44:40.288Zhttps://www.medora.it/Medical/highlights-di-letteratura-hemophilia/safety-and-efficacy-of-valoctocogene-roxaparvovec-with-prophylactic-glucocorticoids-1-year-results-from-the-phase-3b-single-arm-open-label-gener8-3-study.html2026-04-23T14:44:40.326Zhttps://www.medora.it/Medical/highlights-di-letteratura-hemophilia/tafasitamab-lenalidomide-salvage-therapy-dlbcl-geltamo-real-world.html2026-04-23T14:44:40.377Zhttps://www.medora.it/Medical/highlights-di-letteratura-hemophilia/therapeutic-innovations-hemophilia-reinvestment.html2026-04-23T14:44:40.421Zhttps://www.medora.it/Medical/highlights-di-letteratura-hemophilia/transcar-real-world-cd19-car-t-rr-transformed-indolent-lymphomas.html2026-04-23T14:44:40.462Zhttps://www.medora.it/Medical/highlights-di-letteratura-hemophilia/transforming-hemophilia-care-therapeutic-innovations-challenges.html2026-04-23T14:44:40.499Zhttps://www.medora.it/Medical/highlights-di-letteratura-hemophilia/treatment-of-bleeding-episodes-with-efanesoctocog-alfa-in-previously-treated-patients-with-severe-hemophilia-a-in-the-phase-3-xtend-1-study.html2026-04-23T14:44:40.546Zhttps://www.medora.it/Medical/highlights-di-letteratura-hemophilia/tsubasa-study-quality-daily-life-hemophilia-a-emicizumab.html2026-04-23T14:44:40.597Zhttps://www.medora.it/Medical/highlights-di-letteratura-spinal-muscolar-atrophy/Coagulation-factor-VIII-biological-basis-of-emerging-hemophilia-A-therapies.html2026-04-23T14:44:40.641Zhttps://www.medora.it/Medical/highlights-di-letteratura-spinal-muscolar-atrophy/Combination-targeted-therapy-in-relapsed-diffuse-large-B-cell-lymphoma.html2026-04-23T14:44:40.679Zhttps://www.medora.it/Medical/highlights-di-letteratura-spinal-muscolar-atrophy/Epcoritamab-monotherapy-in-patients-with-relapsed-or-refractory-follicular-lymphoma-EPCORE-NHL-1-a-phase-2-cohort-of-a-single-arm-multicentre-study1.html2026-04-23T14:44:40.713Zhttps://www.medora.it/Medical/highlights-di-letteratura-spinal-muscolar-atrophy/Frontline-treatment-of-follicular-lymphoma-what-will-it-take-to-change-current-practice.html2026-04-23T14:44:40.758Zhttps://www.medora.it/Medical/highlights-di-letteratura-spinal-muscolar-atrophy/Glofitamab-in-relapsed-refractory-mantle-cell-lymphoma-results-from-a-phase-I-II-study.html2026-04-23T14:44:40.8Zhttps://www.medora.it/Medical/highlights-di-letteratura-spinal-muscolar-atrophy/Glofitamab-plus-gemcitabine-and-oxaliplatin-GemOx-versus-rituximab-GemOx-for-relapsed-or-refractory-diffuse-large-B-cell-lymphoma-STARGLO-a-global-phase-3-randomised-open-label-trial.html2026-04-23T14:44:40.837Zhttps://www.medora.it/Medical/highlights-di-letteratura-spinal-muscolar-atrophy/Identification-risk-factors-and-clinical-course-of-CNS-relapse-in-DLBCL-patients-across-19-prospective-phase-2-and-3-trials-a-LYSA-and-GLA-DSHNHL-collaboration1.html2026-04-23T14:44:40.871Zhttps://www.medora.it/Medical/highlights-di-letteratura-spinal-muscolar-atrophy/International-Society-on-Thrombointernational-society-on-thrombosis-and-haemostasis-clinical-practice-guideline-for-treatment-of-congenital-haemophilia-a-critical-appraisal.html2026-04-23T14:44:40.901Zhttps://www.medora.it/Medical/highlights-di-letteratura-spinal-muscolar-atrophy/International-Society-on-Thrombosis-and-Haemostasis-clinical-practice-guideline-for-treatment-of-congenital-hemophilia-A-and-B-based-on-the-Grading-of-Recommendations-Assessment-Development-and-Evaluation-methodology.html2026-04-23T14:44:40.939Zhttps://www.medora.it/Medical/highlights-di-letteratura-spinal-muscolar-atrophy/Late-adverse-events-after-chimeric-antigen-receptor-T-cell-therapy-for-patients-with-aggressive-B-cell-Non-Hodgkin-lymphoma.html2026-04-23T14:44:40.989Zhttps://www.medora.it/Medical/highlights-di-letteratura-spinal-muscolar-atrophy/Loncastuximab-tesirine-in-relapsed-refractory-diffuse-large-B-cell-lymphoma-long-term-efficacy-and-safety-from-the-phase-II-LOTIS-2-study.html2026-04-23T14:44:41.088Zhttps://www.medora.it/Medical/highlights-di-letteratura-spinal-muscolar-atrophy/Long-term-3-year-follow-up-of-mosunetuzumab-in-relapsed-or-refractory-follicular-lymphoma-after-2-or-more-prior-therapies.html2026-04-23T14:44:41.14Zhttps://www.medora.it/Medical/highlights-di-letteratura-spinal-muscolar-atrophy/Pain-related-quality-of-life-outcomes-in-people-with-haemophilia-A-receiving-emicizumab-a-post-hoc-analysis-of-the-HAVEN-1-3-and-4-and-STASEY-studies.html2026-04-23T14:44:41.184Zhttps://www.medora.it/Medical/highlights-di-letteratura-spinal-muscolar-atrophy/Polatuzumab-vedotin-plus-bendamustine-and-rituximab-or-obinutuzumab-in-relapsed-refractory-follicular-lymphoma-a-phase-Ib-II-study.html2026-04-23T14:44:41.231Zhttps://www.medora.it/Medical/highlights-di-letteratura-spinal-muscolar-atrophy/Tumor-infiltrating-lymphocytes-and-survival-outcomes-in-early-ERBB2-positive-breast-cancer-10-year-analysis-of-the-ShortHER-randomized-clinical-trial.html2026-04-23T14:44:41.289Zhttps://www.medora.it/Medical/highlights-di-letteratura-spinal-muscolar-atrophy/advancing-hemophilia-treatment-gene-therapy.html2026-04-23T14:44:41.348Zhttps://www.medora.it/Medical/highlights-di-letteratura-spinal-muscolar-atrophy/an-immunogenetic-basis-for-lung-cancer-risk.html2026-04-23T14:44:41.399Zhttps://www.medora.it/Medical/highlights-di-letteratura-spinal-muscolar-atrophy/artificial-intelligence-hemophilia-management-future-directions.html2026-04-23T14:44:41.443Zhttps://www.medora.it/Medical/highlights-di-letteratura-spinal-muscolar-atrophy/cd19-car-t-primary-mediastinal-lbcl-cibmtr-analysis.html2026-04-23T14:44:41.485Zhttps://www.medora.it/Medical/highlights-di-letteratura-spinal-muscolar-atrophy/clinical-outcomes-of-total-knee-arthroplasty-in-patients-who-have-hemophilic-arthropathy-a-prospective-study.html2026-04-23T14:44:41.541Zhttps://www.medora.it/Medical/highlights-di-letteratura-spinal-muscolar-atrophy/clotting-factor-concentrates-hemophilia-children.html2026-04-23T14:44:41.593Zhttps://www.medora.it/Medical/highlights-di-letteratura-spinal-muscolar-atrophy/concizumab-prophylaxis-in-people-with-haemophilia-a-or-haemophilia-b-without-inhibitors-explorer8-a-prospective-multicentre-open-label-randomised-phase-3a-trial.html2026-04-23T14:44:41.637Zhttps://www.medora.it/Medical/highlights-di-letteratura-spinal-muscolar-atrophy/cost-effectiveness-emicizumab-review.html2026-04-23T14:44:41.688Zhttps://www.medora.it/Medical/highlights-di-letteratura-spinal-muscolar-atrophy/durvalumab-with-or-without-tremelimumab-in-combination-with-chemotherapy-as-first-line-therapy-for-metastatic-non-small-cell-lung-cancer-the-phase-iii-poseidon-study.html2026-04-23T14:44:41.731Zhttps://www.medora.it/Medical/highlights-di-letteratura-spinal-muscolar-atrophy/efficacy-safety-satisfaction-emicizumab-hemophilia-a-systematic-review.html2026-04-23T14:44:41.783Zhttps://www.medora.it/Medical/highlights-di-letteratura-spinal-muscolar-atrophy/emicizumab-and-unmet-needs-of-patients-with-hemophilia-a-who-are-managed-with-replacement-therapies.html2026-04-23T14:44:41.82Zhttps://www.medora.it/Medical/highlights-di-letteratura-spinal-muscolar-atrophy/emicizumab-untreated-hemophilia-a-study.html2026-04-23T14:44:41.86Zhttps://www.medora.it/Medical/highlights-di-letteratura-spinal-muscolar-atrophy/extending-health-equity-to-people-with-moderate-and-mild-hemophilia-a-revisiting-the-haven-6-trial.html2026-04-23T14:44:41.9Zhttps://www.medora.it/Medical/highlights-di-letteratura-spinal-muscolar-atrophy/first-in-human-study-nxt007-factor-viii-mimetic-antibody.html2026-04-23T14:44:41.936Zhttps://www.medora.it/Medical/highlights-di-letteratura-spinal-muscolar-atrophy/gene-therapy-hemophilia-care-pathway-isth.html2026-04-23T14:44:41.973Zhttps://www.medora.it/Medical/highlights-di-letteratura-spinal-muscolar-atrophy/gene-therapy-hemophilia-lab-challenges.html2026-04-23T14:44:42.015Zhttps://www.medora.it/Medical/highlights-di-letteratura-spinal-muscolar-atrophy/glofitamab-polatuzumab-efficacy-safety-rr-lbcl-hgbcl-phase1b-2.html2026-04-23T14:44:42.078Zhttps://www.medora.it/Medical/highlights-di-letteratura-spinal-muscolar-atrophy/glofitamab-vs-epcoritamab-cost-analysis-rr-dlbcl.html2026-04-23T14:44:42.116Zhttps://www.medora.it/Medical/highlights-di-letteratura-spinal-muscolar-atrophy/hemophilia-joint-health-score-model-economic-evaluation-prophylaxis.html2026-04-23T14:44:42.161Zhttps://www.medora.it/Medical/highlights-di-letteratura-spinal-muscolar-atrophy/hrqol-physical-activity-joint-health-emicizumab.html2026-04-23T14:44:42.202Zhttps://www.medora.it/Medical/highlights-di-letteratura-spinal-muscolar-atrophy/large-b-cell-lymphoma-eha-clinical-practice-guidelines-diagnosis-treatment-follow-up.html2026-04-23T14:44:42.242Zhttps://www.medora.it/Medical/highlights-di-letteratura-spinal-muscolar-atrophy/lisocabtagene-maraleucel-vs-standard-care-second-line-rr-lbcl-transform-phase3-3yr-followup.html2026-04-23T14:44:42.278Zhttps://www.medora.it/Medical/highlights-di-letteratura-spinal-muscolar-atrophy/marstacimab-treatment-hemophilia-a-b.html2026-04-23T14:44:42.318Zhttps://www.medora.it/Medical/highlights-di-letteratura-spinal-muscolar-atrophy/mosunetuzumab-polatuzumab-transplant-ineligible-rr-lbcl-sunmo-phase3.html2026-04-23T14:44:42.355Zhttps://www.medora.it/Medical/highlights-di-letteratura-spinal-muscolar-atrophy/nupower-nuwiq-perioperative-hemophilia-a.html2026-04-23T14:44:42.391Zhttps://www.medora.it/Medical/highlights-di-letteratura-spinal-muscolar-atrophy/nxt007-first-in-human-study.html2026-04-23T14:44:42.424Zhttps://www.medora.it/Medical/highlights-di-letteratura-spinal-muscolar-atrophy/orthopaedic-surgery-hemophilia-ehl-fusion.html2026-04-23T14:44:42.457Zhttps://www.medora.it/Medical/highlights-di-letteratura-spinal-muscolar-atrophy/patient-perspective-on-disease-burden-and-gene-therapy-for-hemophilia-a-and-b-the-haemvolution-for-patients-italian-survey.html2026-04-23T14:44:42.488Zhttps://www.medora.it/Medical/highlights-di-letteratura-spinal-muscolar-atrophy/pharmacokinetics-concizumab-hemophilia.html2026-04-23T14:44:42.519Zhttps://www.medora.it/Medical/highlights-di-letteratura-spinal-muscolar-atrophy/polarix-subgroup-analysis-older-patients-60-dlbcl-phase3.html2026-04-23T14:44:42.601Zhttps://www.medora.it/Medical/highlights-di-letteratura-spinal-muscolar-atrophy/review-management-relapsed-refractory-follicular-lymphoma-italian-perspective.html2026-04-23T14:44:42.65Zhttps://www.medora.it/Medical/highlights-di-letteratura-spinal-muscolar-atrophy/rituximab-bendamustine-cytarabine-venetoclax-older-highrisk-mcl-fil-v-rbac-phase2.html2026-04-23T14:44:42.694Zhttps://www.medora.it/Medical/highlights-di-letteratura-spinal-muscolar-atrophy/safety-and-efficacy-of-valoctocogene-roxaparvovec-with-prophylactic-glucocorticoids-1-year-results-from-the-phase-3b-single-arm-open-label-gener8-3-study.html2026-04-23T14:44:42.73Zhttps://www.medora.it/Medical/highlights-di-letteratura-spinal-muscolar-atrophy/tafasitamab-lenalidomide-salvage-therapy-dlbcl-geltamo-real-world.html2026-04-23T14:44:42.769Zhttps://www.medora.it/Medical/highlights-di-letteratura-spinal-muscolar-atrophy/therapeutic-innovations-hemophilia-reinvestment.html2026-04-23T14:44:42.813Zhttps://www.medora.it/Medical/highlights-di-letteratura-spinal-muscolar-atrophy/transcar-real-world-cd19-car-t-rr-transformed-indolent-lymphomas.html2026-04-23T14:44:42.913Zhttps://www.medora.it/Medical/highlights-di-letteratura-spinal-muscolar-atrophy/transforming-hemophilia-care-therapeutic-innovations-challenges.html2026-04-23T14:44:42.953Zhttps://www.medora.it/Medical/highlights-di-letteratura-spinal-muscolar-atrophy/treatment-of-bleeding-episodes-with-efanesoctocog-alfa-in-previously-treated-patients-with-severe-hemophilia-a-in-the-phase-3-xtend-1-study.html2026-04-23T14:44:42.987Zhttps://www.medora.it/Medical/highlights-di-letteratura-spinal-muscolar-atrophy/tsubasa-study-quality-daily-life-hemophilia-a-emicizumab.html2026-04-23T14:44:43.027Zhttps://www.medora.it/search.html2026-04-08T14:27:44.945Zhttps://www.medora.it/user.html2025-01-15T17:14:53.302Zhttps://www.medora.it/user/login.html2026-04-17T08:01:28.378Zhttps://www.medora.it/user/register.html2026-04-01T15:33:06.423Zhttps://www.medora.it/user/confirmation.html2025-01-21T14:49:31.519Zhttps://www.medora.it/user/reset-password.html2026-04-01T15:33:33.759Zhttps://www.medora.it/user/login-materiale-educazionale.html2026-03-17T14:09:28.039Zhttps://www.medora.it/servizi.html2026-04-01T14:35:10.861Zhttps://www.medora.it/servizi/Piattaforme.html2026-04-01T14:35:59.778Zhttps://www.medora.it/servizi/Piattaforme/hemo-academy.html2026-04-01T14:37:09.639Zhttps://www.medora.it/servizi/Piattaforme/hemo-academy/community.html2026-04-01T15:05:34.404Zhttps://www.medora.it/servizi/Piattaforme/hemo-academy/community/prima-edizione.html2026-04-01T15:13:18.28Zhttps://www.medora.it/servizi/Piattaforme/hemo-academy/community/seconda-edizione.html2026-04-01T15:14:28.802Zhttps://www.medora.it/servizi/Piattaforme/hemo-academy/news/introduzione-allemofilia.html2026-04-01T15:15:53.04Zhttps://www.medora.it/servizi/Piattaforme/hemo-academy/news/ll-laboratorio-in-emofilia.html2026-04-01T15:19:02.813Zhttps://www.medora.it/servizi/Piattaforme/hemo-academy/news/la-farmacocinetica.html2026-04-01T15:16:29.148Zhttps://www.medora.it/servizi/Piattaforme/hemo-academy/news/evoluzione-terapeutica-in-emofilia.html2026-04-01T15:15:13.751Zhttps://www.medora.it/servizi/Piattaforme/hemo-academy/news/terapia-sostitutiva.html2026-04-01T15:21:47.704Zhttps://www.medora.it/servizi/Piattaforme/hemo-academy/news/terapia-non-sostitutiva.html2026-04-01T15:20:08.042Zhttps://www.medora.it/servizi/Piattaforme/hemo-academy/news/terapia-genica.html2026-04-01T15:19:29.712Zhttps://www.medora.it/servizi/Piattaforme/hemo-academy/comitato-didattico.html2026-04-01T14:40:10.436Zhttps://www.medora.it/servizi/Piattaforme/hemo-academy/survey.html2026-04-01T15:22:37.884Zhttps://www.medora.it/patologie.html2026-04-01T20:38:40.496Zhttps://www.medora.it/patologie/neuroscienze.html2026-04-01T20:51:17.566Zhttps://www.medora.it/patologie/neuroscienze/NMOSD.html2026-04-08T15:02:24.156Zhttps://www.medora.it/patologie/neuroscienze/sclerosi-multipla.html2024-12-09T12:43:58.706Zhttps://www.medora.it/patologie/oncologia.html2026-04-08T14:59:39.631Zhttps://www.medora.it/patologie/oncologia/carcinoma-della-mammella.html2026-04-08T14:59:00.854Zhttps://www.medora.it/patologie/oncologia/nsclc.html2024-12-09T10:58:48.038Zhttps://www.medora.it/patologie/materiale-informativo.html2026-04-09T11:37:19.354Zhttps://www.medora.it/patologie/materiale-informativo/somministrazione-sottocute-un-piccolo-cambiamento-un-grande-impatto.html2026-04-08T22:02:13.839Zhttps://www.medora.it/patologie/materiale-informativo/video-somministrazione-sottocutanea-PH-FDC-SC.html2026-04-08T15:04:31.221Zhttps://www.medora.it/patologie/materiale-informativo/guida-pratica-pdf.html2026-04-08T22:03:24.521Zhttps://www.medora.it/patologie/materiale-informativo/guida-pratica-PH-DC-SC.html2026-04-08T22:02:46.333Zhttps://www.medora.it/patologie/materiale-informativo/video-infusione-Atezolizumab-bevacizumab.html2026-04-08T22:00:52.403Zhttps://www.medora.it/patologie/materiale-informativo/video-di-formazione-somministrazione-sottocutanea-atezolizumab.html2026-03-10T07:52:51.229Zhttps://www.medora.it/patologie/video-somministrazione-sottocutanea-atezolizumab-link.html2026-04-08T14:58:13.922Zhttps://www.medora.it/patologie/video-somministrazione-sottocutanea-atezolizumab-link/che-cosa-e-atezolizumab-e-a-cosa-serve.html2026-04-08T14:57:34.153Zhttps://www.medora.it/patologie/video-somministrazione-sottocutanea-atezolizumab-link/dopo-la-somministrazione-e-conclusioni.html2026-04-08T14:54:07.793Zhttps://www.medora.it/patologie/video-somministrazione-sottocutanea-atezolizumab-link/informazione-al-paziente.html2026-04-08T14:53:15.78Zhttps://www.medora.it/patologie/video-somministrazione-sottocutanea-atezolizumab-link/informazione-sulla-conservazione-di-atezolizumab.html2026-04-08T14:31:45.826Zhttps://www.medora.it/patologie/video-somministrazione-sottocutanea-atezolizumab-link/preparazione-alla-somministrazione.html2026-04-08T14:30:26.707Zhttps://www.medora.it/patologie/video-somministrazione-sottocutanea-atezolizumab-link/preparazione-della-dose.html2026-04-08T14:29:22.936Zhttps://www.medora.it/patologie/video-somministrazione-sottocutanea-atezolizumab-link/somministrazione-di-atezolizumab.html2026-04-08T14:28:43.958Zhttps://www.medora.it/medora-tv.html2026-04-01T20:37:00.502Zhttps://www.medora.it/Eventi.html2026-03-23T13:52:36.968Zhttps://www.medora.it/Eventi/building-bridges-2024.html2026-03-23T13:59:09.585Zhttps://www.medora.it/Eventi/dualanswher2-2025-highlights.html2026-03-23T13:59:50.851Zhttps://www.medora.it/Eventi/dualanswher2-2025-highlights/poligano.html2026-03-23T14:01:47.482Zhttps://www.medora.it/Eventi/dualanswher2-2025-highlights/padova.html2026-03-23T14:01:14.559Zhttps://www.medora.it/Eventi/dual-answher2-2026.html2026-04-20T12:23:20.867Zhttps://www.medora.it/Vabysmo-preparazione-video.html2026-04-01T15:34:09.964Zhttps://www.medora.it/videointervista-drssa-bonanno-aggiornamento-dati-realec.html2026-04-01T15:36:48.788Zhttps://www.medora.it/feel-the-future-the-sound-of-evolution.html2026-03-23T14:03:52.304Zhttps://www.medora.it/footer.html2024-12-18T00:42:06.814Zhttps://www.medora.it/footer/contatti.html2026-03-23T14:04:42.542Zhttps://www.medora.it/footer/informativa-cookie.html2026-03-23T14:05:30.514Zhttps://www.medora.it/footer/informativa-privacy-farmacovigilanza.html2026-03-23T14:06:08.867Zhttps://www.medora.it/footer/privacy-policy.html2026-03-23T14:06:53.069Zhttps://www.medora.it/footer/termini-e-condizioni.html2026-03-23T14:07:27.96Zhttps://www.medora.it/videointervista-dr-bearz-caso-clinico-rozlytrek.html2026-04-01T15:35:48.478Zhttps://www.medora.it/hemo-academy.html2026-03-23T14:11:43.398Zhttps://www.medora.it/Il-Portale-Roche-Foundation-Medicine.html2026-03-23T14:34:29.685Zhttps://www.medora.it/feel-the-future-enlighten-the-way.html2026-03-23T14:02:26.948Zhttps://www.medora.it/highlights-di-letteratura-landing-page.html2026-03-23T14:11:17.655Zhttps://www.medora.it/error-404.html2025-01-15T18:00:14.454Zhttps://www.medora.it/error-403.html2025-01-20T12:35:28.079Zhttps://www.medora.it/ascolta-il-prof-arcaini-su-un-caso-clinico-con-linfoma-follicolare.html2026-03-23T13:20:55.123Zhttps://www.medora.it/vabysmo-video-di-somministrazione.html2026-04-01T15:35:11.2Zhttps://www.medora.it/content-team-templates/materiale-informativo.html2026-03-23T13:30:27.936Zhttps://www.medora.it/content-team-templates/materiale-informativo/guida-pratica-pdf.html2026-03-23T13:48:43.015Zhttps://www.medora.it/content-team-templates/materiale-informativo/guida-pratica-PH-DC-SC.html2026-03-23T13:49:46.041Zhttps://www.medora.it/content-team-templates/materiale-informativo/video-infusione-Atezolizumab-bevacizumab.html2026-03-23T13:50:25.517Zhttps://www.medora.it/content-team-templates/materiale-informativo/video-somministrazione-sottocutanea-PH-FDC-SC.html2026-03-23T13:52:02.853Zhttps://www.medora.it/content-team-templates/materiale-informativo/video-somministrazione-sottocutanea-atezolizumab-link.html2026-03-23T13:51:22.623Zhttps://www.medora.it/gazyvaro-trattamento-di-prima-linea-del-linfoma-follicolare.html2026-03-23T14:08:57.103Zhttps://www.medora.it/gazyvaro-trattamento-di-prima-linea-del-linfoma-follicolare-lf.html2026-03-23T14:09:38.417Zhttps://www.medora.it/gazyvaro-nella-gestione-del-linfoma-follicolare.html2026-03-23T14:08:25.165Zhttps://www.medora.it/testscript.html2026-01-26T14:26:59.33Zhttps://www.medora.it/prova1.html2025-12-01T17:24:45.643Zhttps://www.medora.it/smakers-preview/smakers-programma-faculty.html2026-03-18T11:11:03.735Zhttps://www.medora.it/smakers-preview/smakers-workshop.html2026-04-01T15:32:33.521Zhttps://www.medora.it/smakers-preview/smakers-gallery-foto.html2026-04-01T15:23:09.877Zhttps://www.medora.it/smakers-preview/smakers-informazioni-logistiche.html2026-01-13T11:36:48.108Zhttps://www.medora.it/smakers-preview/smakers-poster.html2026-04-01T15:31:28.52Zhttps://www.medora.it/smakers-preview/SMAkers-overview.html2026-02-11T16:25:16.751Zhttps://www.medora.it/test2.html2025-12-17T13:14:52.163Zhttps://www.medora.it/zoom-prova.html2026-02-09T13:57:52.428Zhttps://www.medora.it/come-somministrare-piasky.html2026-04-15T12:04:37.965Zhttps://www.medora.it/rcp-piasky-branded.html2026-03-27T14:43:17.35Z